BioCentury
ARTICLE | Company News

Amarin cardiovascular news

January 9, 2012 8:00 AM UTC

In a letter to shareholders, Amarin's chairman and CEO, Joseph Zakrzewski, said it is considering three options for commercializing AMR101: partnership, acquisition and self-commercialization with third party support. The company said it has held collaboration discussions with larger pharmaceutical companies and plans to continue these discussions in the future. If the biotech decides to launch AMR101 by itself, it will begin hiring a sales force in the U.S. of about 250-300 close to the time of approval. ...